Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as a first-line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease (BD).
We conducted an open-label multicenter study of IFX versus ADA for BD-related uveitis refractory to conventional nonbiologic treatment. IFX or ADA was chosen as the first-line biologic agent based on physician and patient agreement. Patients received 3–5 mg/kg intravenous IFX at 0, 2, and 6 weeks and every 4–8 weeks thereafter, or 40 mg subcutaneous ADA every other week without a loading dose. Ocular parameters were compared between the 2 groups.
The study included 177 patients (316 affected eyes), of whom 103 received IFX and 74 received ADA. There were no significant baseline differences between treatment groups in main demographic features, previous therapy, or ocular sign severity. After 1 year of therapy, we observed an improvement in all ocular parameters in both groups. However, patients receiving ADA had significantly better outcomes in some parameters, including improvement in anterior chamber inflammation (92.31% versus 78.18% for IFX; P = 0.06), improvement in vitritis (93.33% versus 78.95% for IFX; P = 0.04), and best-corrected visual acuity (mean ± SD 0.81 ± 0.26 versus 0.67 ± 0.34 for IFX; P = 0.001). A nonsignificant difference was seen for macular thickness (mean ± SD 250.62 ± 36.85 for ADA versus 264.89 ± 59.74 for IFX; P = 0.15), and improvement in retinal vasculitis was similar between the 2 groups (95% for ADA versus 97% for IFX; P = 0.28). The drug retention rate was higher in the ADA group (95.24% versus 84.95% for IFX; P = 0.042).
Although both IFX and ADA are efficacious in refractory BD-related uveitis, ADA appears to be associated with better outcomes than IFX after 1 year of follow-up.
- 1, , , , , . Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol 2007; 91: 1579–82.
- 2, . Behçet's syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793–809.
- 3, , , , , . Behçet's disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 2011; 152: 1059–66.
- 4, , , , . Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004; 138: 373–80.
- 5, , , , , . Clinical features of Chinese patients with Behçet's disease. Ophthalmology 2008; 115: 312–8.
- 6, . Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986; 70: 589–92.
- 7. Advancements in the management of uveitis. Best Pract Res Clin Rheumatol 2016; 30: 304–15.
- 8, , , , , . Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121: 785–96.
- 9, , , , , , et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016; 375: 932–43.
- 10, , , , , , et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; 388: 1183–92.
- 11, , , , , , et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol 2016; 68: 1522–30.
- 12, , , , , , et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 2014; 53: 2223–31.
- 13 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078–80.
- 14 International Team for the Revision of the International Criteria for Behçet's Disease. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338–47.
- 15, , , , , , et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 2014; 32 Suppl 84: S54–7.
- 16, , , , , , et al. Anti–interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis–associated uveitis refractory to anti–tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol 2017; 69: 668–75.
- 17, , , , , , et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. Clin Exp Rheumatol 2016; 34 Suppl 102: S34–40.
- 18, , , , , , et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum 2015; 45: 361–8.
- 19, , , , , , et al. Golimumab in uveitis previously treated with other anti-TNF-α drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol 2014; 32: 864–8.
- 20, , , , , , et al. Golimumab in refractory uveitis related to spondyloarthritis: multicenter study of 15 patients. Semin Arthritis Rheum 2016; 46: 95–101.
- 21, , , , , , et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study. Rheumatology (Oxford) 2018; 57: 856–64.
- 22 The Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140: 509–16.
- 23, . International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987; 103: 234–5.
- 24, , , . Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467–71.
- 25, , , , , , et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005; 112: 764–70.
- 26, , , , , , et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575–81.
- 27, , , , , , et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res 2001; 33: 251–5.
- 28, , , , , . Tumour necrosis factor-α levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 2004; 20: 155–7.
- 29, , , . Enhanced production of in vitro tumor necrosis factor-α from monocytes in Behçet's disease. Nippon Ganka Gakkai Zasshi 1992; 96: 1282–5.
- 30, , , , for the Ocular Behçet's Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 2012; 130: 592–8.
- 31, , . Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet disease. Br J Ophthalmol 2011; 95: 549–52.
- 32, , , . Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol 2011; 95: 1245–50.
- 33, , , , , , et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005; 52: 2478–84.
- 34, , , , , , et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46: 1161–4.
- 35, , . Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010; 18: 226–32.
- 36, , , , , . Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int 2011; 31: 243–5.
- 37, , , , , , et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 2012; 51: 1825–31.
- 38, , , , , . Efficacy of adalimumab in Behçet's disease: description of 6 cases. Reumatol Clin 2011; 7: 258–61.
- 39, , , , , , et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013; 40: 74–9.
- 40, , , , , , et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011; 63: 612–8.